Humanwell Healthcare (600079.SH): Abiraterone acetate tablets obtained drug registration certificate.

Humanwell Healthcare (600079.SH) announced that its controlling subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Acetate Abiraterone Tablets. Acetate Abiraterone Tablets are used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including those who have not received hormone therapy or have received hormone therapy for no more than 3 months.